Opinion of the Transparency Council – pironolactonum, goserelinum, leuprorelinum
At its meeting on 13 May 2025, the Transparency Council adopted opinion No. 82/2025 on the reimbursement of medicines containing the active substances spironolactonum, goserelinum, leuprorelinum for indications, dosages or methods of administration other than those specified in the Summary of Product Characteristics, i.e. F64.0 Transgenderism